C-WORTHY

C-WORTHY
Name	C-WORTHY
Purpose	Assessment of cirrhosis risk in patients with chronic hepatitis C
Based on	Clinical trial data from interferon-based and direct-acting antiviral regimens

C-WORTHY. The C-WORTHY score is a validated clinical tool designed to predict the likelihood of cirrhosis development in individuals diagnosed with chronic hepatitis C virus infection. It integrates key patient and disease characteristics to stratify risk, aiding clinicians in treatment prioritization and surveillance planning. The score was derived and validated using data from major clinical trial programs, including studies of boceprevir and sofosbuvir-based therapies.

Overview

The C-WORTHY scoring system provides a quantitative estimate for the risk of progressing to cirrhosis, a serious complication of chronic hepatitis C that can lead to hepatic decompensation and hepatocellular carcinoma. It is intended for use in adult patients prior to the initiation of antiviral therapy. The tool helps identify high-risk individuals who may benefit from more urgent therapeutic intervention and enhanced monitoring, aligning with guidelines from organizations like the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Development and history

The C-WORTHY score was developed through retrospective analysis of patient data from the phase II C-WORTHY trial, a study investigating combinations of sofosbuvir and ledipasvir with or without ribavirin. Researchers from institutions like Mount Sinai Hospital and Gilead Sciences analyzed baseline characteristics associated with fibrosis progression. The model was subsequently validated in independent cohorts from other pivotal trials, such as those for simeprevir and daclatasvir, confirming its predictive accuracy across different genotypes and treatment eras.

Clinical applications

In clinical practice, the C-WORTHY score is primarily used for risk stratification to guide management decisions for patients with chronic hepatitis C. A high score may prompt earlier initiation of direct-acting antiviral therapy and more frequent ultrasound surveillance for hepatocellular carcinoma. It is also utilized in shared decision-making between patients and hepatologists to discuss prognosis and the importance of adherence to treatment. Furthermore, the score has been referenced in health economics studies to model the long-term cost-effectiveness of antiviral therapy in different risk groups.

Scoring system and criteria

The C-WORTHY score is calculated using a points-based system that incorporates several non-invasive variables. Key components include the patient's age, platelet count, aspartate transaminase to alanine transaminase ratio, and results from serologic tests like the FIB-4 index or APRI score. Points are also assigned for the presence of type 2 diabetes and the specific genotype of the hepatitis C virus, with genotype 3 often conferring additional risk. The total points correspond to a risk category, such as low, intermediate, or high probability of developing cirrhosis within a defined timeframe.

Evidence and validation

The predictive validity of the C-WORTHY score has been demonstrated in multiple peer-reviewed studies published in journals such as Hepatology and the Journal of Hepatology. Validation studies have shown consistent discrimination and calibration in diverse populations, including those co-infected with HIV and patients of different ethnicities across North America and Europe. Its performance has been compared favorably to other non-invasive markers like transient elastography and the NAFLD Fibrosis Score in the context of hepatitis C.

Limitations and considerations

While a useful tool, the C-WORTHY score has several limitations. Its predictive accuracy may be reduced in patients with established cirrhosis or those with concurrent alcoholic liver disease or non-alcoholic steatohepatitis. The score was developed in the context of clinical trial populations, which may not fully represent real-world patients with more advanced comorbidities. Furthermore, as treatment paradigms rapidly evolve with newer direct-acting antiviral regimens, the score's relevance to outcomes in the current era of high sustained virological response rates requires ongoing assessment.

Category:Medical scoring systems Category:Hepatology Category:Hepatitis C